These 10 Stocks Blew Past Expectations

Page 9 of 9

1. Vera Therapeutics, Inc. (NASDAQ:VERA)

Vera Therapeutics jumped by 67.49 percent on Monday to close at $31.74 apiece following the success of its pivotal ORIGIN Phase 3 trial for Atacicept—a novel therapy for Berger’s disease, also known as immunoglobulin A nephropathy (IgAN).

In a statement, Vera Therapeutics, Inc. (NASDAQ:VERA) said that it achieved its primary endpoint of reduction in proteinuria (UPCR) during the trial, having decreased by 46 percent from baseline and by 42 percent compared with placebo at week 36.

Other pre-specified endpoints achieved similar or better results compared to the ORIGIN Phase 2b clinical trial

Additionally, Vera Therapeutics, Inc. (NASDAQ:VERA) reported a favorable safety profile for the treatment.

According to the company, it plans to meet with the Food and Drug Administration (FDA) to discuss the results and the regulatory pathway, and submit a Biologics License Application (BLA) in the fourth quarter of 2025.

While we acknowledge the potential of VERA, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than VERA and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires.

Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email below.

Page 9 of 9